16.04.2012 - The Polish government is to ban Monsanto's MON810 maize making it the seventh in the club of EU countries to stop cultivation of the GM crop.
Warsaw – The move follows protests in Warsaw last month by around 1,500 beekeepers and anti-GM protesters who dumped thousands of dead bees on the steps of the Ministry of Agriculture. Agriculture Minister Marek Sawicki has announced that the government would implement a ban on the cultivation of the genetically modified MON 810 maize. The minister claimed the pollen might be responsible for a host of health problems and may even be the cause of the dwindling bee population. The government now wants to pass a law that circumvents the need to obtain EU approval for a ban on any GMO crops. Revised Polish regulations would stipulate that the ban may be implemented and that it will suffice simply to notify the European Commission of the matter. “We are pleasantly surprised that the government is looking for a way of actually implementing the ban,” said Greenpeace spokesman Jacek Winiarski after having a discussion with governmental representatives. If Poland implements the ban, it will follow in the footsteps of Austria, France, Germany, Greece, Hungary and Luxembourg which have all banned the cultivation of MON 810 at different stages, saying it threatens biodiversity.
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.
24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.
20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.
08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.